File(s) under permanent embargo
HIV vaccine rationale, design and testing
journal contributionposted on 2005-04-01, 00:00 authored by K Slobod, C Coleclough, M Bonsignori, S Brown, X Zhan, S Surman, A Zirkel, B Jones, R Sealy, John StambasJohn Stambas, B Brown, T Lockey, P Freiden, P Doherty, J Blanchard, L Martin, J Hurwitz
A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax® presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.
JournalCurrent HIV research
Pagination107 - 112
PublisherBentham Science Publishers Ltd.
Publication classificationC1.1 Refereed article in a scholarly journal
Copyright notice2005 Bentham Science Publishers Ltd.
CategoriesNo categories selected
HIV envelope proteincocktailbreadthScience & TechnologyLife Sciences & BiomedicineImmunologyInfectious DiseasesVirologyHUMAN-IMMUNODEFICIENCY-VIRUSPRIMARY SUBCUTANEOUS VACCINATIONENVELOPE GLYCOPROTEINGAG-POLNEUTRALIZATION SENSITIVITYPASSIVE-IMMUNIZATIONCYNOMOLGUS MONKEYSIMMUNE-RESPONSERHESUS MACAQUESTYPE-1